Astedt B, Bladh B, Christensen U, Lecander I
Scand J Clin Lab Invest. 1985 Sep;45(5):429-35. doi: 10.1080/00365518509155239.
The interaction of tissue plasminogen activator derived from a melanoma cell line with a specific plasminogen activator inhibitor from placental tissue, which inhibits urokinase and tissue plasminogen activator but not plasmin, was studied. Tissue plasminogen activator exists in two forms, a one chain and a two chain molecule. It was found that the two enzyme species each form 1:1 complexes with the inhibitor and that the two chain enzyme binds the inhibitor very strongly, Ki = 3 X 10(-10) mol/l, whereas the one chain enzyme forms a much weaker complex, Ki is approximately 10(-7) to 10(-8) mol/l. Substrate hydrolysis is much more efficiently catalysed by the two chain plasminogen activator than by the one chain activator.
研究了源自黑色素瘤细胞系的组织纤溶酶原激活物与来自胎盘组织的一种特异性纤溶酶原激活物抑制剂之间的相互作用,该抑制剂可抑制尿激酶和组织纤溶酶原激活物,但不抑制纤溶酶。组织纤溶酶原激活物以两种形式存在,即单链分子和双链分子。研究发现,这两种酶分别与抑制剂形成1:1复合物,且双链酶与抑制剂的结合非常紧密,解离常数Ki = 3×10⁻¹⁰mol/L,而单链酶形成的复合物则弱得多,Ki约为10⁻⁷至10⁻⁸mol/L。双链组织纤溶酶原激活物催化底物水解的效率比单链激活物高得多。